Biography
Carin A. Uyl-de Groot studied Health Care Policy and Management at the Erasmus University Rotterdam. From March 1990 onwards she is working at the institute for Medical Technology Assessment/Department of Health Care Policy and Management at the Erasmus Medical Centre Rotterdam. Her research activities are mainly focused on cost-effectiveness analyses of cancer treatments. Quality of life studies are an integral part of these studies. From 1994 she is program leader of cancer studies. Her main interest consists of diagnostics and therapeutic technologies, economic studies linked to clinical studies, modelling studies, cost studies, quality of life studies, methodological issues and implementation studies particularly in the cancer field. She got her PhD in 1995. Since March 2000 she is director of the institute for Medical Technology Assessment. Since November 2005 she has been appointed professor of health technology assessment at the VU University Medical Center in Amsterdam.
Erasmus School of Health Policy & Management
Full professor | Health Technology Assessment (HTA)
- uyl@eshpm.eur.nl
More information
Work
- Carlos Antonio Godoy Junior, Laura Mäkitie, Eleonora Fiorenzato, Maija Koivu, Joonas Niskala, Angelo Antonini, Lytske Jantien Bakker, Luis Pilli, Carin Uyl-de Groot, William Ken Redekop & Welmoed Kirsten van Deen (2025) - Diverse preferences, different solutions: Exploring remote monitoring preferences in Parkinson's disease through a discrete choice experiment - Journal of Parkinson's Disease, 1877718X251327752 - doi: 10.1177/1877718X251327752
- Hedwig M. Blommestein, Saskia de Groot, Brenda Leeneman, Carin A. Uyl-de Groot, John B.A.G. Haanen, Michel W.J.M. Wouters, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Willeke A.M. Blokx, Marye J. Boers-Sonderen, Alfons J.M. van den Eertwegh, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Olivier J. van Not, Astrid A.M. van der Veldt, Karijn P.M. Suijkerbuijk & Margreet G. Franken (2025) - Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model - European Journal of Cancer, 218 - doi: 10.1016/j.ejca.2024.115071 - [link]
- Yi Hsuan Chen, Michiel Kroesen, Mischa Hoogeman, Matthijs Versteegh, Carin Uyl-de Groot & Hedwig M. Blommestein (2025) - Treatment-related toxicity, utility and patient-reported outcomes of head and neck cancer patients treated with proton therapy: A longitudinal study - Clinical and Translational Radiation Oncology, 51 - doi: 10.1016/j.ctro.2025.100913 - [link]
- Dianne Bosch, Kim J.M. van der Velden, Tom Belleman, Welmoed K. van Deen, André M Bergman, Maarten J. van der Doelen, Alfons J M van den Eertwegh, Winald R Gerritsen, Reindert J A van Moorselaar, Diederik M. Somford, Metin Tascilar, Hans M. Westgeest, Carin A Uyl-de Groot, Peter F.A. Mulders, Malou C.P. Kuppen & Inge M. van Oort (2025) - Learning From Evidence: Changes in Real-World Use of Second Androgen Receptor Targeted Treatments in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Clinical Genitourinary Cancer - doi: 10.1016/j.clgc.2025.102317
- Elaine Julian, Tom Belleman, Maria João Garcia, Robin Doeswijk, Rosa Giuliani, Bernhard J. Woermann, Daniel Widmer, Patrick Tilleul, Ruben Casado-Arroyo, Valentina Strammiello, Kate Morgan, Marcus Guardian, Michael Ermisch, Renato Bernardini, Fabrizio Gianfrate, Stefano Capri, Carin de Groot, Mira Pavlovic, Jörg Ruof & Maureen van Molken (2025) - Avoiding Error and Finding the Right Balance in European Health Technology Assessments: Insights Generated by the European Access Academy - Journal of Market Access and Health Policy, 5, 1-16
- Tom Belleman, Jeroen van Wijngaarden, Malou C.P. Kuppen, Saskia de Groot, Kim J. M. van der Velden, Dianne Bosch, Inge M. van Oort, Carin Uyl - de Groot & Welmoed van Deen (2025) - Moving from a registry to a learning health system: A casestudy of a Dutch prostate cancer registry - Learning Health Systems - doi: 10.1002/lrh2.10476 - [link]
- Nicole Huang, Laura A Hatfield, Saeed Al-Azazi, Pieter Bakx, Amitava Banerjee, Nitzan Burrack, Yu Chin Chen, Christina Fu, Carlos Godoy Junior, Renaud Heine, Dennis T. Ko, Lisa M Lix, Victor Novack, Laura Pasea, Feng Qiu, Bheeshma Ravi, Therese A Stukel, Carin de Groot, Peter Cram & Bruce E. Landon (2024) - Comparison of Management and Outcomes of Hip Fractures Among Low- and High-Income Patients in Six High-Income Countries - Journal of General Internal Medicine - doi: 10.1007/s11606-024-09274-9
- Michiel Zietse, Ruben Malmberg, Roelof W.F. van Leeuwen, Frederick W. Thielen & Carin A. Uyl – de Groot (2024) - The administration of immune checkpoint inhibitors via an elastomeric pump versus conventional intravenous infusion: an economic perspective - Bmc Health Services Research, 24 (1) - doi: 10.1186/s12913-024-11719-0 - [link]
- Minka Zivkovic, , , Elisabeth Pols - van Veen, Vossa van der Vegte, Silvie A.E. Sebastian, Annick S. de Moor, Suzanne J.A. Korporaal, Roger Schutgens, Rolf T. Urbanus, Gerard Jansen, Wala Al Arashi, Ryanne Arisz, Ruben Bierings, Johan Boender, Martijn Brands, Annelien Bredenoord, Laura Bukkems, Lex Burdorf, Marjon Cnossen, Tine Goedhart, Jan Hazelzet, Elise Huisman, Nathalie Jansen, Marieke Kruip, Sebastiaan Laan, Frank Leebeek, Nikki van Leeuwen, Hester Lingsma, Moniek de Maat, Karina Meijer, Iris van Moort, Caroline Mussert, Suzanne Polinder, Simone Reitsma, Lorenzo Romano, Saskia Schols & Carin Uyl (2024) - Functional characterization of a nanobody-based glycoprotein VI-specific platelet agonist - Research and Practice in Thrombosis and Haemostasis, 8 (7) - doi: 10.1016/j.rpth.2024.102582 - [link]
- Renaud J.S.D. Heine, Ron H.J. Mathijssen, Floor A.J. Verbeek, Chantal Van Gils & Carin A. Uyl-de Groot (2024) - Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands - Value in Health, 27 (10), 1367-1372 - doi: 10.1016/j.jval.2024.06.003 - [link]
- Carin Uyl - de Groot, Ken Redekop, Amir Ansaripour, K. Zendehdel, N. Tadayon & F. Sadeghi (2016) - Use of data-mining to perform a real world cost analysis of HER2-positive breast cancer in Iran
Cie Beoordeling Oncologische Middelen
- Start date approval
- juli 2022
- End date approval
- juli 2025
- Place
- UTRECHT
Gezondheidsraad
- Start date approval
- juli 2022
- End date approval
- juli 2025
- Place
- DEN HAAG
bestuurslid CPO, Erasmus Medisch Centrum
- Start date approval
- juli 2022
- End date approval
- juli 2025
- Place
- ONBEKEND
Master Thesis Eu-HEM
- Level
- master
- Year Level
- master
- Year
- 2024
- Course Code
- GW4560M
Master Thesis HEPL
- Level
- master
- Year Level
- master
- Year
- 2024
- Course Code
- GW4555M
Master Thesis HE
- Year Level
- master, master
- Year
- 2024
- Course Code
- GW4592M
